Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841778 | 0.87 | BACE1 (0.47) | HRH3KCNH2KDM5AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2916998 | 0.86 | BACE1 (0.46) | HRH3KCNH2KDM5AMEN1KMT2A | |
| SCHEMBL10211722 | 0.82 | HRH3 (0.53) | HRH3KCNH2KDM5AUSP30BTK | |
| SCHEMBL6096866 | 0.80 | HRH3 (0.42) | HRH3KCNH2KDM5AUSP30BTK | |
| SCHEMBL3722676 | 0.80 | HRH3 (0.65) | HRH3KCNH2 | |
| SCHEMBL3731592 | 0.80 | HRH3 (0.89) | HRH3KCNH2 | |
| SCHEMBL4359670 | 0.78 | HPGD (0.59) | CCR5MEN1KMT2ACCR3 | |
| SCHEMBL3722330 | 0.78 | HRH3 (0.90) | HRH3KCNH2 | |
| SCHEMBL2909666 | 0.77 | CCR5 (0.60) | HRH3KCNH2CCR5 | |
| SCHEMBL3725423 | 0.77 | HRH3 (0.90) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | HRH3 1169/4885KCNH2 3180/4885KDM5A 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.